XTX Topco Ltd Buys Shares of 40,120 MiMedx Group, Inc. (NASDAQ:MDXG)

XTX Topco Ltd bought a new stake in shares of MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 40,120 shares of the company's stock, valued at approximately $386,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Jane Street Group LLC raised its position in shares of MiMedx Group by 133.6% during the 3rd quarter. Jane Street Group LLC now owns 305,652 shares of the company's stock worth $1,806,000 after acquiring an additional 174,797 shares in the last quarter. JPMorgan Chase & Co. raised its position in shares of MiMedx Group by 265.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 297,367 shares of the company's stock worth $1,757,000 after acquiring an additional 215,995 shares in the last quarter. Barclays PLC raised its position in shares of MiMedx Group by 163.9% during the 3rd quarter. Barclays PLC now owns 262,449 shares of the company's stock worth $1,550,000 after acquiring an additional 163,005 shares in the last quarter. SG Americas Securities LLC raised its position in shares of MiMedx Group by 79.9% during the 4th quarter. SG Americas Securities LLC now owns 83,385 shares of the company's stock worth $802,000 after acquiring an additional 37,031 shares in the last quarter. Finally, Principal Financial Group Inc. increased its position in MiMedx Group by 6.3% during the third quarter. Principal Financial Group Inc. now owns 55,495 shares of the company's stock worth $328,000 after buying an additional 3,292 shares during the period. 79.15% of the stock is currently owned by hedge funds and other institutional investors.

MiMedx Group Stock Performance

Shares of MDXG stock traded down $0.08 during midday trading on Monday, hitting $6.83. The company had a trading volume of 340,573 shares, compared to its average volume of 685,229. The company's 50 day simple moving average is $7.51 and its 200 day simple moving average is $8.08. MiMedx Group, Inc. has a 52-week low of $5.47 and a 52-week high of $10.14. The stock has a market cap of $1.01 billion, a price-to-earnings ratio of 12.42 and a beta of 1.74. The company has a debt-to-equity ratio of 0.10, a current ratio of 4.10 and a quick ratio of 3.53.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last announced its earnings results on Wednesday, February 26th. The company reported $0.07 earnings per share for the quarter, meeting the consensus estimate of $0.07. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. The company had revenue of $92.91 million for the quarter, compared to the consensus estimate of $89.42 million. Research analysts anticipate that MiMedx Group, Inc. will post 0.3 earnings per share for the current fiscal year.

Insider Buying and Selling at MiMedx Group

In other news, insider Kimberly Maersk-Moller sold 4,106 shares of the stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $7.89, for a total value of $32,396.34. Following the completion of the transaction, the insider now owns 310,836 shares in the company, valued at $2,452,496.04. This trade represents a 1.30 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CAO William Frank Iv Hulse sold 81,446 shares of the stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $7.80, for a total transaction of $635,278.80. Following the completion of the transaction, the chief accounting officer now owns 494,774 shares of the company's stock, valued at $3,859,237.20. This represents a 14.13 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 144,018 shares of company stock worth $1,130,312. 1.30% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

MDXG has been the topic of several research analyst reports. StockNews.com lowered MiMedx Group from a "strong-buy" rating to a "buy" rating in a research report on Wednesday, April 16th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $13.00 price target on shares of MiMedx Group in a research report on Thursday, February 27th.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.